XML 56 R33.htm IDEA: XBRL DOCUMENT v3.25.4
SEGMENTS AND GEOGRAPHIC REGIONS
 12 Months Ended
Dec. 31, 2025
Segment Reporting [Abstract]  
SEGMENTS AND GEOGRAPHIC REGIONS SEGMENTS AND GEOGRAPHIC REGIONS
The Company's segments are aligned with the market verticals they serve, while maintaining integration and innovation strengths within strategic value chains. DuPont is comprised of two operating segments: Healthcare & Water Technologies and Diversified Industrials. Major products by segment include: Healthcare & Water Technologies (specialty components for medical devices, TYVEK® medical packaging and garments, TYCHEM® protective suits, AMBERLITE™ ion exchange resins, FILMTEC™ reverse osmosis and nanofiltration elements and INGE™ and ITEGRATEC™ ultrafiltration modules); and Diversified Industrials (TYVEK® house wrap, STYROFOAM™ insulation, CORIAN® solid surface, Vespel® shapes and parts, MOLYKOTE® specialty lubricants, BETAFORCE™ and BETASEAL™ structural adhesives and Cyrel® flexographic printing plates). The Company operates globally in substantially all of its product lines. Transfers of products between operating segments are generally valued at cost, to the extent such transfers are applicable.

The revenues and certain expenses of the M&M Divestitures, Aramids Business, and Electronics Business are classified as discontinued operations in the current and historical periods. Corporate includes DuPont's equity interest in Derby Holdings Group related to the Delrin® Divestiture.

The costs of the M&M Businesses, Aramids Business, and Electronics Business that are classified as discontinued operations include only direct operating expenses incurred by the businesses. Indirect costs, such as those related to corporate and shared service functions previously allocated to the M&M Businesses, Aramids Business, and Electronics Business, do not meet the criteria for discontinued operations and are reported within continuing operations. A portion of these indirect costs include costs related to activities the Company will or continues to undertake post-closing of the M&M Divestitures, Aramids Divestiture, and Electronics Separation, and for which it is or will be reimbursed (“Future Reimbursable Indirect Costs”). Future Reimbursable Indirect Costs are reported within continuing operations in Corporate but are excluded from Operating EBITDA as defined below. The remaining portion of these indirect costs are not subject to future reimbursement (“Stranded Costs”). Stranded Costs are reported within continuing operations in Corporate and are included within Operating EBITDA.

The Company's measure of profit/loss for segment reporting purposes is Operating EBITDA as this is the manner in which the Company's chief operating decision maker ("CODM"), the Chief Executive Officer, assesses performance and allocates resources. The CODM utilizes Operating EBITDA to assess financial performance and allocate resources by comparing actual results to historical and previously forecasted results. The Company defines Operating EBITDA as earnings (i.e., “Income from continuing operations before income taxes") before interest, depreciation, amortization, non-operating pension / OPEB benefits / charges, and foreign exchange gains / losses, excluding future reimbursable indirect costs, remediation costs associated with divested businesses, and is adjusted for significant items. Reconciliations of these measures are provided on the following pages.
Sales are attributed to geographic regions based on customer location; long-lived assets are attributed to geographic regions based on asset location.
Net Trade Revenue by Geographic Region202520242023
(In millions) For the years ended December 31,
United States$3,188 $3,139 $2,917 
Canada227 232 229 
EMEA 1
1,468 1,379 1,383 
Asia Pacific 2
1,640 1,647 1,754 
Latin America326 322 331 
Total$6,849 $6,719 $6,614 
1.Europe, Middle East and Africa.
2. Net sales attributed to China/Hong Kong, for the years ended December 31, 2025, 2024 and 2023 were $708 million, $763 million, and $851 million, respectively.

Long-lived Assets by Geographic RegionDecember 31,
In millions202520242023
United States$1,964 2,106 2,119 
Canada24 24 21 
EMEA 1
1,151 1,045 1,100 
Asia Pacific288 247 293 
Latin America37 32 34 
Total$3,464 $3,454 $3,567 
1.Europe, Middle East and Africa.
2.Long-lived assets of Luxembourg, for the years ended December 31, 2025, 2024 and 2023 were $784 million, $716 million, and $770 million, respectively.
Segment Revenue, Significant Segment Expenses and Segment Operating EBITDAFor the years ended December 31,
202520242023
In millionsHealthcare & Water TechnologiesDiversified IndustrialsHealthcare & Water TechnologiesDiversified IndustrialsHealthcare & Water TechnologiesDiversified Industrials
Segment net sales$3,233 $3,616 $2,976 $3,743 $2,919 $3,695 
Less 1:
Cost of sales$2,013 $2,422 $1,893 $2,506 $1,839 $2,557 
Selling, general and administrative expenses350 447 329 438 286 391 
Research and development expenses81 93 84 91 75 87 
Amortization of intangibles & other segment items 2
189 97 179 115 170 92 
Add:
Equity in earnings of nonconsolidated affiliates$2 $(1)$1 $1 $1 $— 
Depreciation and amortization 3
370 244 352 245 316 224 
Segment Operating EBITDA$972 $800 $844 $839 $866 $792 
1.The significant expense categories and amounts align with the segment-level information that is regularly provided to the chief operating decision maker.
2.Other segment items include immaterial other gains or losses and miscellaneous income and expenses.
3.Depreciation is a reconciling item to Segment Operating EBITDA as it is included within Cost of sales, "Selling, general and administrative expenses" and "Research and development expenses".

Total reportable segment net sales are $6,849 million, $6,719 million and $6,614 million for the years ended December 31, 2025, 2024 and 2023, respectively.

Reconciliation of Segment Operating EBITDA to Income from continuing operations before income taxesFor the years ended December 31,
In millions202520242023
Healthcare & Water Technologies Segment Operating EBITDA$972 $844 $866 
Diversified Industrials Segment Operating EBITDA800 839 792 
Reportable Segment Operating EBITDA$1,772 $1,683 $1,658 
+
Corporate Operating EBITDA 1
$(144)$(152)$(114)
-Depreciation and amortization647 635 580 
+
Interest income 2
72 74 155 
-
Interest expense 3
311 365 396 
+
Non-operating pension/OPEB benefit credits (costs) 1
5 9 (13)
+
Foreign exchange gains (losses), net 1
(34)(3)(77)
-Future reimbursable indirect costs89 100 106 
-Remediation costs associated with divested businesses12 14 22 
+Significant items charge(412)(380)(784)
Income from continuing operations before income taxes$200 $117 $(279)
1.Corporate includes certain enterprise and governance activities including non-allocated corporate overhead costs and support functions, leveraged services, non-business aligned litigation expenses, DuPont's equity interest in Derby related to the Delrin® Divestiture and other costs not absorbed by reportable segments.
2.The year ended December 31, 2025 excludes accrued interest income earned on employee retention credits and interest earned on cash held in escrow associated with the Qnity financing. Refer to details of significant items below.
3.The year ended December 31, 2025 excludes interest rate swap basis amortization. Refer to details of significant items below.
The following tables summarize the pre-tax impact of significant items that are excluded from Operating EBITDA above:
Significant Items for the Year Ended December 31, 2025Healthcare & Water TechnologiesDiversified IndustrialsCorporateTotal
In millions
Restructuring and asset related charges - net 1
$(16)$(22)$(113)$(151)
Acquisition, integration and separation costs 2
— — (203)(203)
Interest rate swap mark-to-market gain 3
— — 29 29 
Loss on debt extinguishment 4
— — (114)(114)
Qnity financing 5
— — 15 15 
Other benefit (credits), net 6
(3)— 15 12 
Total$(19)$(22)$(371)$(412)
1. Includes restructuring actions and asset related charges. See Note 6 for additional information.
2. Acquisition, integration and separation costs related primarily to the Electronics Separation.
3. The twelve months ended December 31, 2025 includes the non-cash mark-to-market net gain related to the 2022 Swaps and 2024 Swaps offset by the interest settlement loss on the 2022 Swaps. The year ended December 31, 2025 also includes basis amortization on the 2022 Swaps ($2 million pre-tax, reflected in "Interest expense" within the Consolidated Statements of Operations). See Note 21 for additional information.
4. The year ended December 31, 2025 includes $15 million of treasury transaction-related fees in addition to $99 million loss on debt extinguishment related to the Debt Exchange, Special Mandatory Redemption, Consent Solicitation and Tender Offer. Refer to Note 15 for further details.
5. Reflects interest income earned on cash held in escrow associated with the Qnity notes. See Note 15 for additional information.
6. Includes benefits related to an adjustment of the Donatelle contingent earn-out liability ($19 million pre-tax benefit), accrued interest earned on employee retention credits ($11 million pre-tax benefit) and a benefit related to an indemnification receivable for a tax matter ($3 million pre-tax benefit), offset by legal costs within the Healthcare & Water Technologies segment associated with a pending intellectual property matter ($22 million pre-tax cost).

Significant Items for the Year Ended December 31, 2024Healthcare & Water TechnologiesDiversified IndustrialsCorporateTotal
In millions
Restructuring and asset related charges - net 1
$(2)$(55)$— $(57)
Inventory write-offs 2
(25)— — (25)
Acquisition, integration and separation costs 3
(12)— (78)(90)
Loss on debt extinguishment 4
— — (74)(74)
Interest rate swap mark-to-market loss 5
— — (139)(139)
Income tax items 6
— — 7 7 
Other benefit (credits), net 7
(2)— — (2)
Total$(41)$(55)$(284)$(380)
1. Includes restructuring actions and asset related charges. See Note 6 for additional information.
2. Reflects inventory write-offs recorded in “Cost of sales” in connection with restructuring actions. See Note 6 for additional information.
3. Acquisition, integration and separation costs related primarily to the Electronics Separation.
4. Reflects the loss on extinguishment of debt related to the partial redemption of an aggregate principal amount of the 2038 Notes. Refer to Note 15 for further details.
5. Includes the non-cash mark-to-market loss related to the 2022 Swaps and 2024 Swaps including the interest settlement loss on the 2022 Swaps and basis amortization on the 2022 Swaps ($1 million pre-tax, reflected in "Interest expense" within the Consolidated Statements of Operations). Refer to Note 21 for further details.
6. Reflects the impact of an international tax audit.
7. Reflects the amortization of an inventory step-up adjustment related the Donatelle Acquisition.

Significant Items for the Year Ended December 31, 2023Healthcare & Water TechnologiesDiversified IndustrialsCorporateTotal
In millions
Restructuring and asset related charges - net 1
$(22)$(20)$(57)$(99)
Acquisition, integration and separation costs 2
(19)— — (19)
Goodwill impairment charges 3
— (668)— (668)
Other benefit (credits), net 4
— 1 1 2 
Total$(41)$(687)$(56)$(784)
1. Includes restructuring actions and asset related charges. See Note 6 for additional information.
2. Acquisition, integration and separation costs related to the Spectrum Acquisition.
3. Reflects a non-cash goodwill impairment charge in the Protection Reporting unit (aggregation of Safety and Shelter businesses).
4. Includes a gain on divestiture reflected in "Sundry income (expense) – net."
Segment and Corporate InformationHealthcare & Water TechnologiesDiversified IndustrialsCorporateTotal
In millions
For the Year Ended December 31, 2025
Assets of continuing operations$9,463 $7,512 $2,744 $19,719 
Investment in nonconsolidated affiliates— — 111 111 
Capital expenditures133 162 — 295 
For the Year Ended December 31, 2024
Assets of continuing operations$8,994 $7,093 $4,169 $20,256 
Investment in nonconsolidated affiliates2 8 116 126 
Capital expenditures141 153 — 294 
For the Year Ended December 31, 2023
Assets of continuing operations$9,004 $7,402 $5,398 $21,804 
Investment in nonconsolidated affiliates1 8 121 130 
Capital expenditures152 142 — 294 

Total Asset Reconciliation at December 31,202520242023
In millions
Assets of continuing operations$19,719 $20,256 $21,804 
Assets of discontinued operations1,856 16,380 16,748 
Total assets$21,575 $36,636 $38,552 

Capital Expenditure Reconciliation to Consolidated Financial StatementsFor the years ended December 31,
In millions202520242023
Segment and Corporate Totals$295 $294 $294 
Other 1
38 (9)8 
Total$333 $285 $302 
1.Reflects the incremental cash spent or unpaid on capital expenditures; total capital expenditures are presented on a cash basis.